DualityBio and BioNTech update on ADC in solid tumors

7 December 2024

China-based biotech Duality Biologic (DualityBio) announced first data from a global Phase I/IIa clinical trial evaluating BNT324/DB-1311, an investigational next-generation antibody-drug conjugate (ADC) targeting the transmembrane glycoprotein B7-H3.

The data were presented in an oral session at the 2024 European Society of Medical Oncology Asia Annual Meeting (ESMO Asia) in Singapore and showed encouraging antitumor activity alongside a manageable safety profile in heavily pre-treated patients with locally advanced or metastatic solid tumors.

BNT324/DB-1311 is being co-developed by Germany’s BioNTech (Nasdaq: BNTX) and DualityBio under a deal signed last year under which the Chinese firm earned an upfront of $170 million and became eligible for up to $1.5 billion in milestones.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK